Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.34 |
| ▸ | GRM3 | Q14832 | 4/20 | 0.34 |
| ▸ | GRM6 | O15303 | 3/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GRM8 | O00222 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359724 | 0.86 | SLC6A4 (0.35) | SLC6A4GRM2GRM3GRM6GRM4 | |
| SCHEMBL6355678 | 0.82 | HSD11B1 (0.40) | GRM2GRM3GRM6GRM4CYP1A2 | |
| SCHEMBL6362421 | 0.78 | CYP1A2 (0.34) | SLC6A4GRM2GRM3GRM6GRM4 | |
| SCHEMBL6355856 | 0.75 | CYP1A2 (0.42) | SLC6A4GRM2GRM3GRM6GRM4 | |
| SCHEMBL14012882 | 0.75 | GABRR1 (0.36) | SLC6A4GRM2GRM3GRM6GRM4 | |
| SCHEMBL16457638 | 0.73 | — | — | |
| SCHEMBL6355979 | 0.72 | HSD11B1 (0.38) | SLC6A4GRM2GRM3GRM6GRM4 | |
| SCHEMBL15362631 | 0.70 | GABRR1 (0.39) | SLC6A4GRM6GRM4CYP1A2ALDH1A1 | |
| SCHEMBL2178920 | 0.70 | GABRR1 (0.39) | SLC6A4GRM6GRM4CYP1A2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL16669413 | 0.68 | SLC1A2 (0.37) | SLC6A4GRM6GRM4CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250800-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN S | 2005-11-10 | — | — | US | claimed |
| US-20030119858-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2003-06-26 | — | — | US | claimed |
| US-20020019540-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2002-02-14 | — | — | US | claimed |
| US-20050250800-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN S | 2005-11-10 | — | — | US | disclosed |
| US-20030119858-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2003-06-26 | — | — | US | disclosed |
| US-6489352-B2 | ANTIEPILEPTIC AGENTS; NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY | 2002-12-03 | — | — | US | disclosed |
| US-20020019540-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2002-02-14 | — | — | US | disclosed |
| US-6316638-B1 | FOR THERAPY OF EPILEPSY, FAINTNESS ATTACKS, HYPOKINESIA, CRANIAL DISORDERS, NEURODEGENERATIVE DISORDERS, DEPRESSION, ANXIETY, PANIC, PAIN, AND NEUROPATHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY | 2001-11-13 | — | — | US | disclosed |
| EP-1082306-A1 | CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL | WARNER-LAMBERT COMPANY (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999061424-A1 | CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL | WARNER-LAMBERT COMPANY (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250800-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, GABRA6, GABRA2 | SLC6A4 228/4885GRM2 164/4885GRM3 225/4885 |
| US-20020019540-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, SLC18A1, CDR2 | SLC6A4 473/4885GRM2 162/4885GRM3 261/4885 |
| US-20030119858-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, SLC18A1, CDR2 | SLC6A4 473/4885GRM2 162/4885GRM3 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.